Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer

Molecular Therapy

Volumn 7, Issue 3, 2003, Pages 366-374

  Furuhata, Souichi ^a   Ide, Hisamitsu ^a   Miura, Yoshiaki ^a   Yoshida, Teruhiko ^a   Aoki, Kazunori ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Adenovirus; Androgen independent; Gene therapy; Prostate cancer; Rat probasin promoter

Indexed keywords

ADENOVIRUS VECTOR; ANDROGEN; ANDROGEN RECEPTOR; GANCICLOVIR; PROBASIN; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; RETINOIC ACID; RETINOID; RETINOID X RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; RECEPTOR BINDING; TRANSGENE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE;

EID: 0037366192     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(02)00059-X     Document Type: Article

References (37)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. (1999). Cancer statistics, 1999. CA Cancer J. Clin. 49: 8-31.
2. Hussain, M. H., Blumenstein, B., Eisenberger, M., and Crawford, E. D. (1996). Southwest Oncology Group studies in hormone-refractory prostate cancer. Semin. Oncol. 23: 24-27.
3. Gaddipati, J. P., et al. (1994). Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res. 54: 2861-2864.
4. Visakorpi, T., et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9: 401-406.
5. Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5: 280-285.
6. Zhao, X. Y., et al. (2000). Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6: 703-706.
7. Prins, G. S., Sklarew, R. J., and Pertschuk, L. P. (1998). Image analysis of androgen receptor immunostaining in prostate cancer accurately predicts response to hormonal therapy. J. Urol. 159: 641-649.
8. Sadi, M. V., Walsh, P. C., and Barrack, E. R. (1991). Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67: 3057-3064.
9. Jarrard, D. F., et al. (1998). Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 58: 5310-5314.
10. Pang, S. (2000). Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther. 7: 991-996.
11. Latham, J. P., Searle, P. F., Mautner, V., and James, N. D. (2000). Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 60: 334-341.
12. Ide, H., Osada, Y., Yoshida, T., and Terada, M. (1999). Evaluation of prostate-specific promoters for a suicide gene therapy of prostate cancer. Nishinihon J. Urol. 57: 412-417.
13. Brookes, D. E., Zandvliet, D., Watt, F., Russell, P. J., and Molloy, P. L. (1998). Relative activity and specificity of promoters from prostate-expressed genes. Prostate 35: 18-26.
14. Martiniello-Wilks, R., et al. (1998). In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Ther. 9: 1617-1626.
15. Russell, P. J., et al. (1998). Prostate cancer gene therapy. Australas. Biotechnol. 8: 99-106.
16. Martiniello-Wilks, R., et al. (2002). Transcription-targeted gene therapy for androgen-independent prostate cancer. Cancer Gene Ther. 9: 443-452.
17. Rennie, P. S., et al. (1993). Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol. Endocrinol. 7: 23-36.
18. Patrikainen, L., Shan, J., Porvari, K., and Vihko, P. (1999). Identification of the deoxyribonucleic acid-binding site of a regulatory protein involved in prostate-specific and androgen receptor-dependent gene expression. Endocrinology 140: 2063-2070.
19. Beato, M. (1989). Gene regulation by steroid hormones. Cell 56: 335-344.
20. Koshiuka, K., et al. (2000). Novel therapeutic approach: organic arsenical (melarsoprol) alone or with all-trans-retinoic acid markedly inhibits growth of human breast and prostate cancer cells in vitro and in vivo. Br. J. Cancer 82: 452-458.
21. Evans, T. R., and Kaye, S. B. (1999). Retinoids: present role and future potential. Br. J. Cancer 80: 11-8.
22. Aoki, K., et al. (2001). Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Ther. 8: 508-514.
23. Aoki, K., Baker, C., Danthinne, X., Imperiale, M. J., and Nabel, G. J. (1999). Efficient generation of recombinant adenoviral vectors by Cre-lox recombination in vitro. Mol. Med. 5: 224-231.
24. Aoki, K., et al. (2000). Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy. Mol. Ther. 1: 555-565.
25. Chlenski, A., Nakashiro, K., Ketels, K. V., Korovaitseva, G. I., and Oyasu, R. (2001). Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 47: 66-75.
26. Vainio, H., and Rautalahti, M. (1999). An international evaluation of the cancer preventive potential of vitamin A. Cancer Epidemiol. Biomarkers Prev 8: 107-109.
27. Lotan, Y., et al. (2000). Differential expression of nuclear retinoid receptors in normal and malignant prostates. J. Clin. Oncol. 18: 116-121.
28. Conley, B. A., et al. (1997). Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol. 39: 291-299.
29. Eastham, J. A., et al. (1996). Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther. 7: 515-523.
30. Hall, S. J., et al. (1999). Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther. 6: 54-63.
31. Blackburn, R. V., Galoforo, S. S., Corry, P. M., and Lee, Y. J. (1998). Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells. Cancer Res. 58: 1358-1362.
32. Lee, C. H., Liu, M., Sie, K. L., and Lee, M. S. (1996). Prostate-specific antigen promoter driven gene therapy targeting DNA polymerase-alpha and topoisomerase II alpha in prostate cancer. Anticancer Res. 16: 1805-1811.
33. Yu, D., et al. (2001). Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther. 8: 628-635.
34. Matuo, Y., et al. (1985). Localization of prostatic basic protein ("probasin") in the rat prostate by use of monoclonal antibody. Biochem. Biophys. Res. Commun. 130: 293-300.
35. Marcelli, M., Haidacher, S. J., Plymate, S. R., and Birnbaum, R. S. (1995). Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 136: 1040-1048.
36. Campbell, M. J., Park, S., Uskokovic, M. R., Dawson, M. I., and Koeffler, H. P. (1998). Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog. Endocrinology 139: 1972-1980.
37. Marshall, E. (1999). Gene therapy death prompts review of adenovirus vector. Science 286: 2244-2245.